Brief: Unicycive Announces Exclusive License And Development Agreement With Lee’S Pharmaceutical Holdings Limited For Renazorb In China And Certain Other Asian Markets

Lees Pharmaceutical Holdings

18/07/2022 12:09

July 18 (Reuters) - Lee's Pharmaceutical Holdings Ltd
 0950.HK :
    * UNICYCIVE ANNOUNCES EXCLUSIVE LICENSE AND DEVELOPMENT
AGREEMENT
WITH LEE’S PHARMACEUTICAL HOLDINGS LIMITED FOR RENAZORB IN CHINA
AND CERTAIN OTHER ASIAN MARKETS
    * UNICYCIVE THERAPEUTICS INC - AGREEMENT INCLUDES UPFRONT
PAYMENT,
ROYALTIES AND MILESTONE PAYMENTS
    * UNICYCIVE THERAPEUTICS- TO RECEIVE AN UPFRONT PAYMENT OF
$1.0
MILLION UPON SIGNATURE & UP TO $1.0 MILLION IN MILESTONE
PAYMENTS UPON PRODUCT LAUNCH IN CHINA
    * UNICYCIVE THERAPEUTICS INC - UNDER DEAL, WILL BE ELIGIBLE
FOR
TIERED ROYALTIES UPON ACHIEVEMENT OF PRESPECIFIED REGULATORY AND
COMMERCIAL ACHIEVEMENTS
    * UNICYCIVE THERAPEUTICS- UNDER DEAL, LEE PHARM TO BE
RESPONSIBLE
FOR DEVELOPMENT, REGISTRATION FILING AND APPROVAL FOR RENAZORB
IN LICENSED TERRITORIES
    * UNICYCIVE THERAPEUTICS- LEE PHARM TO HAVE SOLE
RESPONSIBILITY
FOR IMPORTATION OF DRUG PRODUCT FROM CO
    * UNICYCIVE THERAPEUTICS INC -  LEE PHARM WILL HAVE SOLE
RESPONSIBILITY FOR COSTS OF COMMERCIALIZATION OF RENAZORB IN
LICENSED TERRITORIES

Source text for Eikon:  ID:nGNX9xtl89 
Further company coverage:  0950.HK 

 ((Reuters.Briefs@thomsonreuters.com;))